Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Patient-derived neomorphic SEPTIN6 mutations induce hematopoietic stem cell senescence underlying congenital neutropenia and myelodysplasia
Safa F. Mohamad, Meaghan McGuinness, Yu Zhou, Xin Jiang, Gabriele Casirati, Adele Mucci, Sara Canovas Nunes, Akiko Shimamura, Pietro Genovese, David A. Williams
Safa F. Mohamad, Meaghan McGuinness, Yu Zhou, Xin Jiang, Gabriele Casirati, Adele Mucci, Sara Canovas Nunes, Akiko Shimamura, Pietro Genovese, David A. Williams
View: Text | PDF
Research Article Hematology Oncology

Patient-derived neomorphic SEPTIN6 mutations induce hematopoietic stem cell senescence underlying congenital neutropenia and myelodysplasia

  • Text
  • PDF
Abstract

Septins are RAS-like GTP-binding proteins involved in cytoskeletal organization and cellular division. We previously described 2 pediatric patients harboring SEPT6 germline mutations (GM1: SEPT6 c.1282T>C and GM2: SEPT6 c.1282T>A) presenting with congenital neutropenia associated with the development of myelodysplastic syndrome. In one patient, an additional somatic mutation (SM: SEPT6 c.43C>T) was detected at a low allelic fraction in the BM. Here, we describe the consequences of these mutations for hematopoiesis. Transgenic expression or gene editing of GM1 or GM2 in human CD34+ cells led to enlarged, multinucleated cells associated with accelerated exhaustion and premature senescence of hematopoietic stem and progenitor cells (HSPCs). Senescence defects were associated with the upregulation of mTOR phosphorylation, and pharmacologic inhibition of the mTOR pathway resulted in rescue of senescence. In parallel, HSPCs exhibited marked mitochondrial abnormalities, including increased expression of OPA-1, a key regulator of mitochondrial fusion, and enhanced oxygen consumption during mitochondrial respiration. Introduction of the SM in cis with GM1 mitigated all observed defects. Collectively, our findings demonstrate a gain-of-function mechanism underlying marrow failure in patients carrying germline SEPT6 mutations and suggest that acquisition of a secondary somatic SEPT6 variant may confer a compensatory effect within hematopoietic cells.

Authors

Safa F. Mohamad, Meaghan McGuinness, Yu Zhou, Xin Jiang, Gabriele Casirati, Adele Mucci, Sara Canovas Nunes, Akiko Shimamura, Pietro Genovese, David A. Williams

×

Figure 7

Rescue of premature senescence in human CD34+ cells caused by GM1.

Options: View larger image (or click on image) Download as PowerPoint
Rescue of premature senescence in human CD34+ cells caused by GM1.
(A an...
(A and B) A β-gal assay was performed on human CD34+ cells to determine the percentage of senescent cells on day 7 (D7) (A) and D15 (B) after LVV transduction. β-Gal+ cells were counted to determine percentage senescence. n = 3. Dotted line represents EV control. Controls are the same as Figure 4, A and B. (C) On D7 after lentiviral transduction, GFP+ cells were collected to quantify CyclinD1 mRNA expression. n = 3. (D and E) Western blot densitometric analysis of cyclin D1 (D) and OPA-1 (E). Blots are shown in Supplemental Figure 4, B and C, respectively. n = 3. (F) Transduced cells were sorted 5 days after LVV transduction for GFP+CD34+CD45RA–EPCR+. One day after sorting, cells were subjected to a mitochondrial stress test to determine the OCR at various time points. Arrows indicate injection of various stressors: oligomycin (Oligo), carbonyl cyanite-4 (trifluoromethoxy) phenylhydrazone (FCCP), rotenone/antimycin A (R/A), and 2-deoxy-D-arabino-hexose (2DG). Figure 4H and Figure 7F were performed during the same experimental set up. n = 3. (G) Western blot (left panel) and densitometric analysis (right panel) of phosphorylated mTOR at the Ser2481 position. GAPDH was used as an internal loading control. (H) Transduced GFP+ cells were sorted and plated 2 days after transduction in methylcellulose containing 25 nM rapamycin. Colonies were counted 14 days after plating. n = 3 independent experiments performed in triplicate. (I and J) A β-gal assay was performed on human CD34+ cells to determine the percentage of senescent cells on D7 (I) and D15 (J) after LVV transduction. Rapamycin (25 nM) was added to the culture every 7 days. β-Gal+ cells were counted to determine percentage senescence. n = 3. Data presented as mean ± SD (A–E and G–J) or mean ± SEM (F). All experiments were analyzed using 1-way ANOVA followed by Tukey’s multiple comparisons test as a post hoc analysis. *P < 0.05; **P < 0.005.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts